VASOPRESSIN INJECTION USP SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

VASOPRESSIN

Disponibbli minn:

SANDOZ CANADA INCORPORATED

Kodiċi ATC:

H01BA01

INN (Isem Internazzjonali):

VASOPRESSIN (ARGIPRESSIN)

Dożaġġ:

20UNIT

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

VASOPRESSIN 20UNIT

Rotta amministrattiva:

INTRAMUSCULAR

Unitajiet fil-pakkett:

2/5ML

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

PITUITARY

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0106469001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2005-08-19

Karatteristiċi tal-prodott

PRESCRIBING INFORMATION
PR
VASOPRESSIN INJECTION USP
Sterile Solution; 20 USP pressor units / mL
For Intramuscular (IM) or Subcutaneous (SC) Injection
Antidiuretic Agent
Sandoz Canada Inc.
Date of Revision: August 26, 2020
110 Rue De Lauzon
Boucherville
Quebec
Canada J4B 1E6
Control No.: 216180
Vasopressin Injection USP
Page 2 of 5
VASOPRESSIN INJECTION USP
20 USP pressor units / mL
Sterile
THERAPEUTIC CLASSIFICATION
Antidiuretic Agent
PHARMACOLOGY
Vasopressin Injection USP is a synthetic water-soluble pressor
principle identical in sequence to
arginine vasopressin.
Vasopressin exerts its antidiuretic action by increasing the
reabsorption of water by the renal
tubules. The drug also can cause contraction of smooth muscle of the
gastrointestinal tract and of
all parts of the vascular beds, especially the capillaries, small
arterioles, and venules, with less
effect on the smooth musculature of the large veins.
The direct effect on the contractile elements is neither antagonized
by adrenergic blocking agents
nor prevented by vascular denervation.
Vasopressin Injection USP is intended for intramuscular (IM) or
subcutaneous (SC) injection.
INDICATIONS AND CLINICAL USE
Vasopressin Injection USP is intended for use in the prevention or
treatment of post-operation
abdominal distention, dispelling of gas shadows in abdominal
roentgenography and symptomatic
control of diabetes insipidus.
CONTRAINDICATIONS
Vasopressin Injection USP should not be used in patients having
cardiorenal disease with
hypertension, advanced arteriosclerosis, coronary thrombosis, angina
pectoris, epilepsy or toxemia
of pregnancy. Anaphylaxis or hypersensitivity to the drug or its
components are also
contraindications.
Chronic nephritis with nitrogen retention may be a contraindication
(see PRECAUTIONS).
WARNINGS
Vasopressin Injection USP should not be used except with extreme
caution in patients with
Vasopressin Injection USP
Page 3 of 5
vascular disease, especially disease of the coronary arteries. In such
patients even small doses of
the drug may